Efficacy of cognitive-behavioural therapy for lifestyle modification in metabolic syndrome: a randomised controlled trial with a 18-months follow-up

Silva, Jaqueline Garcia da; Borrego, Ismael Ramón Sánchez; Navarrete, Nuria Navarrete; Peralta-Ramírez, María Isabel; Águila, Fernando Jaén; Caballo, Vicente E.

doi:10.1080/08870446.2022.2055023

Cited by 4 publications

(2 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Andreae and colleagues [ 46 ] argued that CBT-based programs improved depressive symptoms in individuals with diabetes and chronic pain in a randomized controlled trial. In addition, Jaqueline and colleagues [ 47 ] investigated the effectiveness of CBT on patients with MS and results indicated that intervention group patients improved more in negative emotions of anger. Previous research [ 48 ] has shown that individuals with type 2 diabetes and metabolic syndrome who experience psychological stress are at risk of exhibiting inadequate self-care behaviors, which can lead to poor management of their condition.…”

Section: Discussionmentioning

confidence: 99%

The evaluation of cognitive-behavioral therapy-based intervention on type 2 diabetes patients with comorbid metabolic syndrome: a randomized controlled trial

Buys

Ferguson

et al. 2023

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Cognitive behavior therapy (CBT) has been applied in intervention research in diabetes patients with satisfying results. However, there was no research on type 2 diabetes (T2DM) patients with comorbidities. This study aimed to investigate the effectiveness of CBT on psychological variables, behavior variables, quality of life, sleep quality, and physical variables among adult T2DM patients with comorbid metabolic syndrome (MS). Methods 281 patients aged 18–75 years were recruited from Ningbo First Hospital in China from October 2021 to March 2022. Patients were randomized to the intervention group (IG, N = 148) or control group (CG, N = 133). Patients in the IG received 12 CBT-based sessions during a six-month intervention time. Patients in the CG received the usual care only. Univariate General Linear Model was used to analyze the effect of CBT-based interventions. The analysis was conducted by SPSS Version 28. Results Results indicated that CBT-based intervention was superior in the following aspects: relieving depression symptoms: IG (4.11 ± 4.35 vs. 1.99 ± 2.12), CG (3.40 ± 3.26 vs. 2.32 ± 1.88), interaction effect (F = 4.074, P = 0.044); enhancing diabetes self-care behaviors: IG (26.79 ± 12.18 vs. 37.49 ± 10.83), CG (25.82 ± 13.71 vs. 31.96 ± 11.72), interaction effect (F = 5.242, P = 0.022); promoting the efficacy of CBT: IG (47.45 ± 6.83 vs. 50.76 ± 4.98), CG (46.74 ± 6.94 vs. 47.87 ± 5.11), interaction effect (F = 5.198, P = 0.023); improving subjective sleep quality: IG (0.93 ± 0.68 vs. 0.69 ± 0.63), CG (1.03 ± 0.72 vs. 1.01 ± 0.68), interaction effect (F = 3.927, P = 0.048). Conclusions The CBT-based intervention was beneficial in improving depression symptoms, diabetes self-care behaviors, the efficacy of CBT, and sleep quality in T2DM patients with comorbid MS. The downtrend of body mass index, systolic blood pressure, diastolic pressure, and glycated hemoglobin was larger in the intervention group but not to a significant level. Trial registration: This study has been prospectively registered at Australia New Zealand Clinical Trials Registry (Registration ID: ACTRN12621001348842 website: https://www.anzctr.org.au/trial/MyTrial.aspx).

show abstract

Section: Discussionmentioning

confidence: 99%

The evaluation of cognitive-behavioral therapy-based intervention on type 2 diabetes patients with comorbid metabolic syndrome: a randomized controlled trial

Buys

Ferguson

et al. 2023

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…Moreover, diabetes mellitus has been identified as one of the risk factors responsible for up to one-third of AD cases and represents an important modifiable target for preventing dementia at the population level (McGrath et al, 2020 ). Cognitive-behavioral therapy for lifestyle modification in patients with metabolic syndrome effectively reduces cardiovascular risk (Garcia-Silva et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

The A-to-Z factors associated with cognitive impairment. Results of the DeCo study

Gil-Peinado,

Alacreu,

Ramos

et al. 2023

Front. Psychol.

View full text Add to dashboard Cite

IntroductionCognitive impairment (CI) is known to be mediated by several risk and protective factors, many of which are potentially modifiable. Therefore, it is important to have up-to-date studies that address a standard assessment of psychosocial, clinical and lifestyle variables.Materials and methodsWe conducted a cross-sectional observational study, with a 24-month timeframe, to estimate the relationship between risk and protective factors associated with dementia, according to the A-to-Z Dementia Knowledge. Participants were considered at CI risk if they tested positive for at least one of three validated CI screening tests: The Memory Impairment Screening, Short Portable Mental State Questionnaire, and Semantic Verbal Fluency. The A-to-Z data Collection included Mediterranean Diet Adherence Screener and Geriatric Depression Scale.ResultsThe estimated prevalence of CI was 22.6% in a sample of 709 patients with an average of 69.3±10.3 years. The risk factors gradually associated with cognitive decline were hypertension, loneliness, and depression. In contrast, the protective factors gradually associated with less cognitive decline were internet use, reading, and intellectually stimulating jobs. Finally, living alone, having diabetes, taking benzodiazepines, and sleeping more than 9 h were statistically significant associated with CI, whereas to do memory training or a family history of dementia was characteristic of patients without CI.ConclusionA joint assessment of the influence of psychosocial, clinical, and lifestyle-related factors is needed to develop dementia prevention strategies.

show abstract

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Alkhouri,

Edwards,

Berman

et al. 2024

Gastro Hep Advances

View full text Add to dashboard Cite

Efficacy of cognitive-behavioural therapy for lifestyle modification in metabolic syndrome: a randomised controlled trial with a 18-months follow-up

Cited by 4 publications

References 71 publications

The evaluation of cognitive-behavioral therapy-based intervention on type 2 diabetes patients with comorbid metabolic syndrome: a randomized controlled trial

The evaluation of cognitive-behavioral therapy-based intervention on type 2 diabetes patients with comorbid metabolic syndrome: a randomized controlled trial

The A-to-Z factors associated with cognitive impairment. Results of the DeCo study

A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Contact Info

Product

Resources

About